Related Articles
Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice
Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes
Non‑alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review)
Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism
Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway